BioPharma Resources

Drug Trial Radar · NCT05686070

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 12,327 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,327

Actual

Start

Jan 26, 2023

Primary completion

Oct 23, 2025

Study completion Oct 23, 2025

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jan 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had: * an acute stroke due to a blood clot that formed outside the heart (acute non-cardioembolic ischemic stroke), or * TIA/mini-stroke with a high risk of turning into a stroke (high-risk transient ischemic attack), and who are planned to receive standard of care therapy. Acute ischemic strokes or TIA/mini-stroke result from a blocked or reduced blood flow to a part of the brain. They are caused by blood clots that travel to the brain and block the vessels that supply it. If these blood clots form elsewhere than in the heart, the stroke is called non-cardioembolic. People who already had a non-cardioembolic stroke are more likely to have another stroke. This is why they are treated preventively with an antiplatelet therapy, the current standard of care. Antiplatelet medicines prevent platelets, components of blood clotting, from clumping together. Anticoagulants are another type of medicine that prevents blood clots from forming by interfering with a process known as coagulation (or blood clotting). The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care without increasing the risk of bleeding. The main purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or TIA/mini-stroke when given in addition to standard antiplatelet therapy. A placebo is a treatment that looks like a medicine but does not have any medicine in it. Another aim is to compare the occurrence of major bleeding events during the study between the asundexian and the placebo group. Major bleedings have a serious or even life-threatening impact on a person's health. Dependent on the treatment group, the participants will either take asundexian or placebo once a day for at least 3 months up to 31 months. Approximately every 3 months during the treatment period, either a phone call or a visit to the study site is scheduled on an alternating basis. In addition, one visit before and up to two visits after the treatment period are planned. During the study, the study team will: * Check vital signs such as blood pressure and heart rate * Examine the participants' heart health using an electrocardiogram (ECG) * Take blood samples * Ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.

Conditions

  • Prevention of Ischemic Stroke
  • Acute Non-cardioembolic Ischemic Stroke
  • High-risk Transient Ischemic Attack

Interventions

  • Asundexian (BAY2433334)Drug

    Once daily, oral

  • PlaceboDrug

    Placebo to asundexian, once daily, oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of ischemic strokeTime frame: Up to 31 months
  2. Time to first occurrence of ISTH major bleedingTime frame: Up to 31 months

Locations

741 sites in 37 countries. Site status is shown where the registry gives one.

  • Eastern Shore Research Institute, LLC | Fairhope, AL

    Fairhope, Alabama

  • Barrow Neurologic Institute - Petznick Stroke Center

    Phoenix, Arizona

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • Banner - University Medical Center Tucson - Neurology

    Tucson, Arizona

  • University of Arkansas for Medical Sciences - Neurology

    Little Rock, Arkansas

  • Kaiser Permanente Fontana Medical Center

    Fontana, California

  • Long Beach Medical Center - Neurology

    Long Beach, California

  • Kaiser Permanente Los Angeles Medical Center - Neurology

    Los Angeles, California

  • Los Angeles - USC Healthcare Center 2 - Neurology

    Los Angeles, California

  • UCLA NeuroTranslational Research Center

    Los Angeles, California

  • Hoag Memorial Hospital - Center for Research & Education

    Newport Beach, California

  • UCI Medical Center - Neurology

    Orange, California

  • San Francisco VA Health Care System

    San Francisco, California

  • Cottage Health | Santa Barbara Cottage Hospital - Research Department

    Santa Barbara, California

  • The Lundquist Institute - Neurology

    Torrance, California

  • St. Vincent's Medical Center - Neurology Clinic

    Bridgeport, Connecticut

  • Nuvance Health

    Danbury, Connecticut

  • Yale University | School of Medicine - Department of Neurology

    New Haven, Connecticut

  • ChristianaCare Health Services | Christiana Hospital - Emergency Medicine Research

    Newark, Delaware

  • HCA Florida JFK Hospital - Neurology

    Atlantis, Florida

  • Delray Medical Center - Neurology

    Boynton Beach, Florida

  • Nova Clinical Research - Blake Medical Center

    Bradenton, Florida

  • BayCare Health System | Morton Plant Hospital - Neuroscience Research department

    Clearwater, Florida

  • UF Health Neuromedicine Hospital

    Gainesville, Florida

  • Baptist Health Research Institute

    Jacksonville, Florida

  • Intercoastal Medical Group | Clinical Research

    Sarasota, Florida

  • USF Health South Tampa Center for Advanced Healthcare - Neurology

    Tampa, Florida

  • BayCare Health System | Saint Joseph's Hospital - Neurology Department

    Tampa, Florida

  • University of Illinois Hospital - Neurology

    Chicago, Illinois

  • The University of Chicago Medical Center - Neurology

    Chicago, Illinois

  • Loyola University Medical Center - Neurology

    Maywood, Illinois

  • Mercyhealth Javon Bea Hospital - Riverside | Neurology Research Department

    Rockford, Illinois

  • HSHS St. John's Hospital - Neurology

    Springfield, Illinois

  • Baptist Health Lexington

    Lexington, Kentucky

  • Ochsner Medical Center - New Orleans - Neurology

    New Orleans, Louisiana

  • University of Maryland Medical Center - Neurology Care Center

    Baltimore, Maryland

  • Tufts Medical Center - Neurology

    Boston, Massachusetts

  • Henry Ford Hospital - Neurology

    Detroit, Michigan

  • MSU Health Care Neurology & Ophthalmology

    East Lansing, Michigan

  • Trinity Health | Oakland Hospital - Clinical Research Department

    Pontiac, Michigan

Showing 40 of 741 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.